🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot

RecruitingPhase 2, Phase 3Ages 18 Years - 85 YearsAllJonathan Beaudoin
NCT07539298 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn whether valsartan can slow the progression of atrial functional mitral regurgitation (AFMR) in adults with preserved left ventricular ejection fraction. The study will also evaluate the safety and tolerability of valsartan in this population. The main questions it aims to answer are: * Does treatment with valsartan reduce the progression of atrial functional mitral regurgitation compared with placebo? * Does valsartan have favorable effects on mitral valve leaflet remodeling and related cardiac structure and function? * Is valsartan safe and well tolerated in patients with atrial functional mitral regurgitation who do not currently require angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Researchers will compare valsartan to a placebo (a look-alike substance with no active drug) to see if valsartan reduces the progr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. No evidence of mitral organic disease 2. At least moderate left atrial dilatation (left atrial volume index ≥34 mL/m²) 3. Normal (≥ 50%) left ventricular ejection fraction and 4. At least moderate MR grade by multiparametric assessment. Exclusion Criteria: 1. Inability to provide informed consent 2. Indication for or ongoing treatment with ACEI/ARB 3. History of hypotension 4. Hypertension (\>140/90 mmHg) \* 5. Planned cardiac surgery (CABG or valve) 6. Ongoing or planned pregnancy 7. Chronic renal failure with eGFR \< 30 mL/min/1.73m2 8. Neurocognitive disorder 9. History of hyperkalemia 10. Medication interacting with valsartan
💊

What it tests

  • Valsartan
  • Placebo
📍

Where

1 site
Institut universitaire de cardiologie et de pneumologie de Québec-ULaval
Québec, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy